Navigation Links
KaloBios Provides Update on KB001-A Partnership and Clinical Status
Date:7/28/2014

ctable="on">Pseudomonas aeruginosa (Pa) infection. KaloBios is conducting a 180 patient Phase 2 study in cystic fibrosis (CF) subjects with chronic Pa lung infection. KaloBios has received Orphan Drug designation from both the U.S. FDA and the European Medicines Agency for KB001-A for the treatment of Pa lung infection in CF patients. KB001-A has also received Fast Track Status from the U.S. FDA for the prevention of ventilator associated pneumonia. KaloBios is planning to seek a partner to help accelerate the development of this program.
  • KB004 is an anti-EphA3 mAb with potential in treating hematologic malignancies and solid tumors. KaloBios is running an ongoing Phase 1/2 study evaluating KB004 in hematologic malignancies. The Phase 1 dose escalation portion of that study in subjects with hematologic malignancies is ongoing. KaloBios initiated the Phase 2 expansion portion of the study focused on patients with certain EphA3 positive hematologic malignancies in early 2014.
  • KB003 is an anti-GM-CSF mAb with potential to treat inflammatory diseases that was being developed for the treatment of severe asthma. In early 2014, KaloBios completed a Phase 2 clinical study in 160 patients with severe asthma which did not meet its primary endpoint of improvement in FEV1 from baseline as compared to placebo. As a result, KaloBios discontinued development of this compound in severe asthma, and is continuing to analyze the Phase 2 data to review with thought leaders. KaloBios is currently evaluating other possible indications in order to determine next steps, if any, in the development of KB003.
  • All of the company's antibodies were generated using its proprietary Humaneered® technology, a method that converts nonhuman antibodies (typically mouse) into recombinant antibodies that have a high binding affinity to their target a
    '/>"/>

    SOURCE KaloBios Pharmaceuticals, Inc.
    Copyright©2014 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6

    Related medicine technology :

    1. KaloBios Pharmaceuticals Announces Pricing of Initial Public Offering
    2. KaloBios Pharmaceuticals Completes Initial Public Offering
    3. KaloBios Presents Clinical Results with Anti-GM-CSF Antibody in Persistent Asthma Data from KB002 Phase 1/2 Study Presented at the American Academy of Allergy, Asthma and Immunology Meeting
    4. KaloBios Presents Clinical Results with Anti-GM-CSF Antibody in Persistent Asthma
    5. Bioassociate Announces Initiation of Coverage on KaloBios Pharmaceuticals, Inc.
    6. KaloBios to Present at Future Leaders in the Biotech Industry Conference
    7. KaloBios Targeted Antibacterial KB001-A to be Featured in BIO 2013 Panel Discussion of "New Defenses Against Old Enemies"
    8. KaloBios to Present at Needham Healthcare Conference
    9. KaloBios Reports First Quarter 2013 Financial Results
    10. KaloBios to Present at Stifel Healthcare Conference 2013
    11. KaloBios KB001 Anti-Pseudomonas Antibody Study Published in Pediatric Pulmonology
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:10/22/2014)... -- Antigen Discovery Inc. (ADi), a privately held company ... receipt of a National Institutes of Health (NIH) Phase ... of Dental and Craniofacial Research (NIDCR). The one-year $225,000 ... Microarray Chip, which will contain every protein in all ... the development of safe and effective vaccines and therapies ...
    (Date:10/22/2014)... 2014  Paper Pak Industries, a manufacturer of ... Body Guard Bio, a disposable, highly absorbent ... and virus while protecting service providers and the ... a rugged, external nylon shell, watertight zipper, thermal ... inner chamber that contains contaminated and potentially contagious ...
    (Date:10/22/2014)... 2014  With a vision to ensure safety ... Global Pharmaceutical and Biotech manufacturer selects and implements ... solution to protect their animal health brand.  ... Photo - http://photos.prnewswire.com/prnh/20141021/153439 ... aggregated by the Xyntek and Antares solution is ...
    Breaking Medicine Technology:Biomarker Discovery Company, Antigen Discovery Inc., Awarded an NIH Phase I Small Business Innovation Research Grant to Develop a Pan-HIV Protein Microarray Chip 2New, State-Of-The-Art Body Bag Minimizes The Spread Of Bacteria And Virus 2Xyntek and Antares Serialization Solution Protects Pets Too! 2
    ... 2011 Healthpoint today announced the launch of a ... Biotherapeutics, along with an updated brandmark and corporate tagline, ... is designed to communicate the company,s commitment to scientific ... contribute to improved outcomes and quality of life for ...
    ... Md., Feb. 23, 2011 The Cystic Fibrosis Foundation and ... development that targets the defective protein that causes cystic fibrosis, ... The trial was designed to evaluate patients age ... a CF mutation called G551D. The study included 161 patients ...
    Cached Medicine Technology:Healthpoint Launches New Corporate Identity 2Healthpoint Launches New Corporate Identity 3Phase 3 Study of VX-770 Shows Marked Improvement in Lung Function Among People with Cystic Fibrosis with G551D Mutation 2Phase 3 Study of VX-770 Shows Marked Improvement in Lung Function Among People with Cystic Fibrosis with G551D Mutation 3
    (Date:10/25/2014)... WA (PRWEB) October 25, 2014 Homeowners ... insulation has ‘gone bad’ need wonder no more. Clean ... that homeowners should watch out for when it comes ... insulation, according to the article released by Clean Crawls, ... for homeowners that any insulation that has deteriorated, become ...
    (Date:10/25/2014)... Raleigh, NC (PRWEB) October 25, 2014 ... patient who continued to receive pemetrexed (Alimta), after his ... to read the full story , just posted on ... study from Uji Tokushukai Medical Center in Japan suggests ... for mesothelioma patients who cannot tolerate higher ...
    (Date:10/25/2014)... -- Interrupting blood supply to an arm or a leg ... the surgery, according to a new study. "During ... the heart to be able to operate on it. After ... ability to produce energy because it doesn,t get oxygen. When ... such as an arm or a leg, the body prepares ...
    (Date:10/25/2014)... Not getting the right amount of sleep might raise ... Those who sleep less or more than the ... more prone to developing the chronic condition, which causes ... concluded that duration and quality of sleep are key ... diseases. "Both short and long durations of sleep ...
    (Date:10/25/2014)... 23, 2014 (HealthDay News) -- A large influx of ... is to avoid tens of thousands of deaths from ... researchers predict. Using a specially designed mathematical ... the outbreak in just one densely populated county of ... city of Monrovia. The researchers said that if ...
    Breaking Medicine News(10 mins):Health News:5 Signs Indicating That Insulation Needs Replacing as Told By Clean Crawls in Recent Article 2Health News:New Report Illustrates Extended Mesothelioma Survival with “Maintenance Therapy”, According to Surviving Mesothelioma 2Health News:Brief Interruption of Blood Supply to Limb Might Aid Heart Surgery: Study 2Health News:Sleep Duration Linked to Ulcerative Colitis Risk in Study 2Health News:Experts Predict 'Catastrophic' Ebola Epidemic in West Africa if Aid Delayed 2
    ... Despite initiatives, level of diversity among faculty, practitioners still ... say , ANN ARBOR, Mich. , Jan. ... medical school faculty remains low, even as the U.S. population ... currently being trained in medicine is unlikely to reverse those ...
    ... , Jan. 28 PDL BioPharma, Inc. (PDL) (Nasdaq: PDLI ... in 2010. Each of the dividends will be $0.50 per share. ... to all stockholders who own shares of PDL on March 15, 2010 ... October 1, 2010 to all stockholders who own shares of PDL on ...
    ... , ... of Hematology (ASH) now offers physicians who diagnose and treat ... (CME) credits while staying abreast of the latest clinical strategies ... with Medscape, an online network of medical content for physicians ...
    ... , BRIGHTON, Mich. , ... alcohol and drug treatment provider in North America, has signed a ... a Saudi Arabian company to build a 291,000 square-foot, 250 ... the entire Islamic Mideast. , Brighton Hospital, the Addiction Treatment ...
    ... for ovarian cancer does not appear to detect early-stage ovarian ... 1 out of 100 women in the general population with ... in the Journal of the National Cancer Institute . ... in Seattle assessed the predictive value of certain symptoms, including ...
    ... vaccine developed using non-infectious virus-like particles (VLP) has ... mosquito-borne pathogen that has infected millions of people ... researchers at the National Institutes of Health have ... Allergy and Infectious Diseases (NIAID) developed the vaccine ...
    Cached Medicine News:Health News:More Recruiting of Underrepresented Minorities Needed at U.S. Medical Schools, Study Says 2Health News:More Recruiting of Underrepresented Minorities Needed at U.S. Medical Schools, Study Says 3Health News:PDL BioPharma Announces Two $0.50 Dividends in 2010 2Health News:Hematologists Can Now Earn CME Credits Through the Journal Blood 2Health News:Hematologists Can Now Earn CME Credits Through the Journal Blood 3Health News:St. John Health System Brighton Hospital Signs Letter of Intent to Assist Saudi Arabia in Developing New Addiction Treatment Hospital in Riyadh 2Health News:St. John Health System Brighton Hospital Signs Letter of Intent to Assist Saudi Arabia in Developing New Addiction Treatment Hospital in Riyadh 3Health News:St. John Health System Brighton Hospital Signs Letter of Intent to Assist Saudi Arabia in Developing New Addiction Treatment Hospital in Riyadh 4Health News:Symptoms have little value for early detection of ovarian cancer 2Health News:Virus-like particle vaccine protects monkeys from chikungunya virus 2
    ... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
    ... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
    ... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
    ... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
    Medicine Products: